HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Submit an electronic Letter to the Editor about this paper Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (4) Citing Articles via Google Scholar Google Scholar Articles by Chan, P. C. R. Articles by Cole, D. E.C. Search for Related Content PubMed PubMed Citation Articles by Chan, P. C. R. Articles by Cole, D. E.C. Related Collections Molecular Diagnostics and Genetics

Simple and Rapid Detection of BRCA1 and BRCA2 Mutations by Multiplex Mutagenically Separated PCR

¹ Departments of Laboratory Medicine and Pathobiology;
² Genetic Repository, Toronto General Hospital, Toronto, Ontario, Canada M5G 2C4;
³ Department of Pathology and Laboratory Medicine and Centre for Cancer Genetics, Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada M5G 1X5;
⁴ Medicine and Pediatrics (Genetics), University of Toronto, Toronto, Ontario, Canada M5G 1L5;
^a address correspondence to this author at: Department of Laboratory Medicine and Pathobiology, Rm. 402, Banting Institute, 100 College St., University of Toronto, Toronto, Ontario, Canada M5G 1L5: fax 416-978-5650, e-mail davidec.cole@utoronto.ca

BRCA1 and BRCA2 are tumor suppressor genes that are inactivated during neoplastic development (1)(2). Germline mutations of the two genes are transmitted in the autosomal dominant fashion and predispose carriers to the development of ovarian and/or breast cancers (3)(4). Mutations in BRCA1 are present in approximately one-half of the early-onset breast cancer families and 80% of the early-onset breast and ovarian cancer families (5), whereas BRCA2 mutations are believed to account for a comparable percentage of inherited breast cancer cases (6). Women with germline mutations in BRCA1 have a lifetime risk of 85% and up to 50% for breast and ovarian cancers, respectively.

In individuals of Ashkenazi Jewish background, mutations such as 185delAG and 5382insC in BRCA1, and 6174delT in BRCA2 are present in higher frequencies than other mutations because of founder effects (6)(7)(8). In one study, the three mutations accounted for 62% of Ashkenazi patients with ovarian and/or breast cancer (7). The high frequency of these mutations in the BRCA genes indicates their potential role in identifying individuals at risk.

Many methods have been reported for the study of BRCA mutations, including allele-specific oligonucleotide hybridization (8)(9), allele-specific PCR (10), PCR-mediated site-directed mutagenesis (11)(12), heteroduplex analysis (HDA) (13)(14)(15), single-strand conformation polymorphism (14)(16), and . . . [Full Text of this Article]

Acknowledgments

Footnotes

References

The following articles in journals at HighWire Press have cited this article:

				J. Rogozinska-Szczepka, B. Utracka-Hutka, E. Grzybowska, B. Maka, E. Nowicka, A. Smok-Ragankiewicz, H. Zientek, J. Steffen, and A. Wojciechowska-Lacka BRCA1 and BRCA2 mutations as prognostic factors in bilateral breast cancer patients Ann. Onc., September 1, 2004; 15(9): 1373 - 1376. [Abstract] [Full Text] [PDF]